Ahsen Seyrek, Team Lead at BTHT, shared a post on LinkedIn:
“GSK expands its oncology pipeline with a new antibody-drug conjugate for prostate cancer.
GSK has signed a licensing deal with Syndivia for a preclinical ADC targeting advanced castration-resistant prostate cancer (CRPC), valued at up to £268 million ($358 million).
- The drug, built on Syndivia’s GeminiMab conjugation technology, aims for precise tumour targeting and fewer off-target effects.
- It is Syndivia’s first external ADC partnership, a milestone for the French biotech.
- For GSK, the candidate adds to its growing ADC portfolio and follows the return of Blenrep for multiple myeloma.
- It also complements GSK’s B7H3-targeted ADC licensed from Hansoh in 2023, which showed encouraging results at ESMO.
mCRPC affects up to 20% of the 1.4 million men diagnosed with prostate cancer each year, with limited treatment options and a low five-year survival rate.”
More posts about Prostate Cancer.